Ó³»­´«Ã½

One of the primary limitations to the effectiveness of cancer therapeutics is . This month , Ó³»­´«Ã½ researchers Rick Wilson, Levi Garraway, and colleagues describe their work unraveling drug resistance mechanisms for ALK tyrosine kinase inhibitors in ALK-dependent non-small cell lung cancers. They screened nearly 16,000 corresponding to over 12,000 genes, identifying a range of known mechanisms able to confer resistance to ALK inhibitors, along with new ones including purinergic P2Y receptors (G-protein coupled receptors) acting through Protein Kinase C signaling.